RAD001

ApprovedSmall molecule

Novartis

RAD001 is one of 880 small molecule programs targeting Colorectal Carcinoma. It is currently in Approved.

Indications

103

Total Trials

Active Trials

879

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

PTEN Hamartoma Tumor SyndromeActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerActive, not recruiting

Vestibular SchwannomaActive, not recruiting

Systemic MastocytosisActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Colorectal CarcinomaPhase 1/Phase 2

Active, not recruiting

PTEN Hamartoma Tumor SyndromePhase 1/Phase 2

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerApproved

Active, not recruiting

Vestibular SchwannomaPhase 2

Active, not recruiting

Systemic MastocytosisPhase 2

Active, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Showing 10 of 43 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

RAD001

Novartis

Approved

8 2

Avastin

Adenocard

1 4

Voltaren

Novartis

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Refractory

NCT00819546

Q2 2028

Phase 2Active, not recruiting

Endometrial Cancer

NCT01068249

Clinical

Trials by Indication[1]

Breast Cancer8 trials

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

Unknown status·GGBG Forschungs GmbH·Phase 2·NCT00466102·130 enrolled

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00253318·15 enrolled

RAD001 Plus Carboplatin in Breast Cancer Patients

Completed·NNYU Langone Health·Phase 2·NCT01127763·25 enrolled

Show 5 more trials

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Terminated·NNational Cancer Center, Korea·Phase 1/2·NCT01939418·23 enrolled

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

Completed· Novartis logo

Novartis·Phase 4·NCT01743560·52 enrolled

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00574366·14 enrolled

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Unknown status·MM.D. Anderson Cancer Center·Phase 2·NCT00499603·62 enrolled

Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy

Completed·MM.D. Anderson Cancer Center·Preclinical·NCT00317720·40 enrolled

Non-Small Cell Lung Cancer4 trials

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Completed·EEmory University·Phase 1·NCT00401778·33 enrolled

Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00892801·5 enrolled

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Terminated·EEmory University·Phase 1/2·NCT00406276·28 enrolled

Show 1 more trial

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed· Novartis logo

Novartis·Phase 2·NCT00124280·85 enrolled

Prostate Cancer4 trials

Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

Unknown status·SSheba Medical Center·Phase 2·NCT00657982·15 enrolled

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Completed·—·Phase 2·NCT00630344·36 enrolled

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Completed·—·Phase 2·NCT00629525·35 enrolled

Show 1 more trial

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Completed·—·Phase 1/2·NCT00459186·19 enrolled

Kidney Cancer4 trials

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

Completed·TThe Methodist Hospital Research Institute·Phase 1/2·NCT00448149·55 enrolled

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT00446368·66 enrolled

Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00392821·78 enrolled

Show 1 more trial

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00719264·365 enrolled

Renal Cell Carcinoma4 trials

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Completed·—·Phase 1/2·NCT01510119·40 enrolled

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Completed·SSeoul National University Hospital·Phase 2·NCT00830895·49 enrolled

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Completed· Novartis logo

Novartis·Phase 4·NCT01206764·143 enrolled

Show 1 more trial

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT01491672·134 enrolled

53 more indications

Metastatic3 trials

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

Completed· Novartis logo

Novartis·Phase 3·NCT00410124·416 enrolled

RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01009346·9 enrolled

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Completed· Novartis logo

Novartis·Phase 1·NCT01590199·18 enrolled

Endometrial Cancer3 trials

Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Completed·YYale University·Phase 1·NCT00703807·10 enrolled

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01068249·42 enrolled

A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00087685·35 enrolled

Small Cell Lung Cancer3 trials

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Completed· Novartis logo

Novartis·Phase 1·NCT00456833·248 enrolled

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Terminated·UUniversity of California, Davis·Phase 1·NCT00807755·5 enrolled

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Completed·AAhmad Tarhini·Phase 2·NCT00374140·40 enrolled

Gastric Cancer3 trials

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Completed·—·Phase 2·NCT00729482·54 enrolled

Gastric Cancer RAD001 Study

Completed·—·Phase 1/2·NCT01514110·35 enrolled

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Completed·—·Phase 2·NCT01482299·45 enrolled

Neuroendocrine Tumors3 trials

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00843531·17 enrolled

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Completed·—·Phase 1·NCT00942682·21 enrolled

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Completed·—·Phase 1·NCT00804336·22 enrolled

Hepatocellular Carcinoma3 trials

RAD001 in Advanced Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 1/2·NCT00516165·28 enrolled

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

Terminated· Novartis logo

Novartis·Phase 1·NCT00828594·130 enrolled

Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)

Unknown status·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT00390195·134 enrolled

Vestibular schwannoma3 trials

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Completed·NNYU Langone Health·Phase 1·NCT01880749·5 enrolled

Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01490476·10 enrolled

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT01345136·4 enrolled

Locally Advanced Head and Neck Cancer2 trials

Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 1/2·NCT01333085·49 enrolled

RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Terminated·—·Phase 1·NCT01058408·3 enrolled

Pancreatic Cancer2 trials

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Completed·—·Phase 2·NCT00409292·33 enrolled

Phase II Study of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00640978·16 enrolled

Tuberous Sclerosis2 trials

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Completed· Novartis logo

Novartis·Phase 3·NCT01713946·366 enrolled

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Completed·MMustafa Sahin·Phase 2·NCT01289912·52 enrolled

Chemotherapy2 trials

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00714025·40 enrolled

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

Terminated·UUniversity of Chicago·Phase 1·NCT01063478·3 enrolled

Patients With Advanced Solid Tumors2 trials

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00985374·11 enrolled

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00303732·37 enrolled

Pulmonary Neuroendocrine Tumor2 trials

Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Completed· Novartis logo

Novartis·Phase 1·NCT01324492·16 enrolled

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Unknown status·GGuangdong Provincial People's Hospital·Phase 1/2·NCT01175096·20 enrolled

Lung Cancer2 trials

Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

Completed· Novartis logo

Novartis·Phase 1·NCT00457119·69 enrolled

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Completed· Novartis logo

Novartis·Phase 4·NCT01317615·49 enrolled

Colorectal Cancer2 trials

Phase II Trial of RAD001 in Refractory Colorectal Cancer

Completed·SSwedish Medical Center·Phase 2·NCT00337545·22 enrolled

Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

Completed·HHoosier Cancer Research Network·Phase 1/2·NCT00522665·41 enrolled

Multiple Myeloma2 trials

RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Completed·MMassachusetts General Hospital·Phase 1·NCT00729638·28 enrolled

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00474929·103 enrolled

Renal Transplant Recipients2 trials

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

Terminated· Novartis logo

Novartis·Phase 4·NCT00956293·207 enrolled

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01544491·106 enrolled

Neuroendocrine Carcinoma2 trials

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00607113·41 enrolled

Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00113360·67 enrolled

Head and Neck Cancer2 trials

RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

Terminated·Hhoward safran·Phase 1·NCT01057277·3 enrolled

Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00942734·49 enrolled

Gastric Carcinoma1 trial

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

Completed·KKrankenhaus Nordwest·Phase 3·NCT01248403·300 enrolled

Retroperitoneal Sarcoma1 trial

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01048723·2 enrolled

Fallopian Tube Cancer1 trial

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Completed·UUniversity of Pittsburgh·Phase 2·NCT01031381·50 enrolled

PTEN hamartoma tumor syndrome1 trial

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Completed·—·Phase 1/2·NCT02991807·46 enrolled

Metastatic Renal Cell Cancer1 trial

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00529802·60 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated·—·Phase 2·NCT00978432·50 enrolled

Pheochromocytoma1 trial

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

Completed·SSeoul National University Hospital·Phase 2·NCT01152827·33 enrolled

Capecitabine1 trial

Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

Terminated·SStanford University·Phase 1·NCT00473005·18 enrolled

Thyroid Cancer1 trial

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Completed·—·Phase 2·NCT00936858·50 enrolled

Myeloid Leukemia1 trial

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT01188889

Adenoid Cystic Carcinoma1 trial

Study of RAD001 in Adenoid Cystic Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT01152840·33 enrolled

Cholangiocarcinoma1 trial

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol

Unknown status·AAustin Health·Phase 2·NCT00973713·27 enrolled

Cervical Cancer1 trial

Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer

Withdrawn·AAccelerated Community Oncology Research Network·Phase 1·NCT00967928

Refractory1 trial

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Active, not recruiting·RRichard Stone, MD·Phase 1·NCT00819546·29 enrolled

Malignant Neoplasm1 trial

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Completed·—·Phase 1·NCT00927966·21 enrolled

Urothelial Carcinoma1 trial

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma

Terminated·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT00933374·28 enrolled

Esophageal Cancer1 trial

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Completed·EEmory University·Phase 1·NCT01490749·17 enrolled

Malignancies1 trial

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Terminated· Novartis logo

Novartis·Phase 1·NCT04895748·40 enrolled

Colorectal Carcinoma1 trial

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Completed·UUniversity of Utah·Phase 1/2·NCT01047293·47 enrolled

Advanced Head and Neck Cancer1 trial

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Completed·EEmory University·Phase 1/2·NCT01283334·20 enrolled

Gastrointestinal Stromal Tumor1 trial

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Completed· Novartis logo

Novartis·Phase 1/2·NCT01275222·117 enrolled

Mantle Cell Lymphoma1 trial

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00081874·29 enrolled

Pancreatic Neuroendocrine Tumor1 trial

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Completed·—·Phase 1/2·NCT00576680·43 enrolled

Angiomyolipoma1 trial

RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM

Completed·—·Phase 1/2·NCT00457964·36 enrolled

Plexiform Neurofibroma1 trial

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01412892·30 enrolled

Monotherapy1 trial

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Completed· Novartis logo

Novartis·Phase 2·NCT00688753·92 enrolled

Macroglobulinemia1 trial

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00976248·33 enrolled

Advanced Sarcoma1 trial

RAD001 in Advanced Sarcoma

Completed·—·Phase 2·NCT01830153·41 enrolled

Clear Cell Renal Carcinoma1 trial

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00323739·80 enrolled

Low Grade Glioma1 trial

Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01158651·23 enrolled

Lymphoma1 trial

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

Completed·SSamsung Medical Center·Phase 1/2·NCT01198665·46 enrolled

Acute Myeloid Leukemia1 trial

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Unknown status·BBayside Health·Phase 1·NCT00636922·40 enrolled

Systemic Mastocytosis1 trial

Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00449748·10 enrolled

Unspecified1 trial

Phase I Study of Patupilone and RAD001

Completed·UUniversity of Medicine and Dentistry of New Jersey·Phase 1·NCT00496600·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 103 trial records for RAD001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAD001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAD001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

RAD001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Breast Cancer8 trials

Non-Small Cell Lung Cancer4 trials

Prostate Cancer4 trials

Kidney Cancer4 trials

Renal Cell Carcinoma4 trials

Metastatic3 trials

Endometrial Cancer3 trials

Small Cell Lung Cancer3 trials

Gastric Cancer3 trials

Neuroendocrine Tumors3 trials

Hepatocellular Carcinoma3 trials

Vestibular schwannoma3 trials

Locally Advanced Head and Neck Cancer2 trials

Pancreatic Cancer2 trials

Tuberous Sclerosis2 trials

Chemotherapy2 trials

Patients With Advanced Solid Tumors2 trials

Pulmonary Neuroendocrine Tumor2 trials

Lung Cancer2 trials

Colorectal Cancer2 trials

Multiple Myeloma2 trials

Renal Transplant Recipients2 trials

Neuroendocrine Carcinoma2 trials

Head and Neck Cancer2 trials

Gastric Carcinoma1 trial

Retroperitoneal Sarcoma1 trial

Fallopian Tube Cancer1 trial

PTEN hamartoma tumor syndrome1 trial

Metastatic Renal Cell Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Pheochromocytoma1 trial

Capecitabine1 trial

Thyroid Cancer1 trial

Myeloid Leukemia1 trial

Adenoid Cystic Carcinoma1 trial

Cholangiocarcinoma1 trial

Cervical Cancer1 trial

Refractory1 trial

Malignant Neoplasm1 trial

Urothelial Carcinoma1 trial

Esophageal Cancer1 trial

Malignancies1 trial

Colorectal Carcinoma1 trial

Advanced Head and Neck Cancer1 trial

Gastrointestinal Stromal Tumor1 trial

Mantle Cell Lymphoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

Angiomyolipoma1 trial

Plexiform Neurofibroma1 trial

Monotherapy1 trial

Macroglobulinemia1 trial

Advanced Sarcoma1 trial

Clear Cell Renal Carcinoma1 trial

Low Grade Glioma1 trial

Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Systemic Mastocytosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News